new england journal of medicine tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Read the full SURPASS-CVOT trial Read now: The SURPASS-EARLY trial

You want to know: how your appetite changed whether your training performance held up whether GI symptoms are settling whether your A1C, waist, or fasting glucose moved That is the kind of data that tells you whether a compound is helping or just making the scale look good for a while

Read next Doctor Marianne Guenot is a science reporter based in the UK who writes about health, AI, nuclear sciences, archeology, solar and planetary sciences, space exploration, and the commercial and political impact of science and tech

usually mentioned as mild to moderate and temporary as dose escalation is intended, so in most cases, they are resolved after the maintenance dose is reached (153)

JendleJNauckMAMatthewsDRFridAHermansenKDringMet al